Image Sourced HealthScope
Market Herald logo


Be the first with the news that moves the market
  • Healthscope CEO and Managing Director, Gordon Ballantyne has resigned
  • Gordon Ballantyne has a degree in Electric and Electronic Engineering from the University of Heriot-Watt and over 20 years of experience in senior leadership positions

Healthscope, a leading private healthcare provider in Australia and New Zealand, has announced its current Managing Director and CEO Gordon Ballantyne will be leaving the company in June this year.

Gordon joined the Company in May 2017 and played an exceptional role as Chief Executive Officer for patients, employees and shareholders.

Ballantyne’s views on providing an outstanding quality of care for patients aligned with Healthscope’s mission and enabled it to carry out ‘positive and enduring cultural change’ across the organisation.

Gordon Ballantyne graduated from Heriot-Watt University in Edinburgh, with a Bachelor of Science, majoring in Electrical and Electronic Engineering. He spent 20 years in senior leadership roles in global organisations such as Hewlett Packard, T-Mobile, Dell and Dell Ventures. 

Prior to commencing at Healthscope, Ballantyne was the Group Executive of Telstra’s domestic retail business, which he helped to grow into an $18 billion business as well as creating Telstra Health.

“His record as Managing Director and Chief Executive Officer of Healthscope during this challenging period has been exemplary. On behalf of the Board I would like to thank him for his contribution and wish him well,” said company Chairman Paula Dwyer.

“We have reset the business with a clear purpose and strategy, substantially improved financial performance, continued to invest to support future growth, while being uncompromising in our ambition to be a market leader in clinical outcomes and patient care across the industry,” he said.

In relation to his departure, the former CEO simply stated it was time pursue new opportunities.

HSO by the numbers
More From The Market Herald

" Invex Therapeutics (ASX:IXC) receives UK approval to start phase III Presendin trial

Invex Therapeutics (ASX:IXC) has been given the tick of approval in the UK to start its…
Bluechiip (ASX:BCT) - Managing Director, Andrew McLellan

" Bluechiip (ASX:BCT) banks $1.09m R&D tax incentive refund

Bluechiip (ASX:BCT) has received $1.09 million research and development (R&D) tax incentive refund from the Australian…

" Oceania Healthcare (ASX:OCA) announces $500m sustainability-linked loan

Oceania Healthcare (ASX:OCA) has implemented its $500 million five-year sustainability-linked loan (SLL) to support its commitment…
Nyrada (ASX:NYR) - CEO, James Bonnar

" Nyrada (ASX:NYR) announces start date for cholesterol lowering program

Nyrada (ASX:NYR) announces its first-in-human study for cholesterol lowering is expected to begin during the first…